We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BIOCRATES and ALTANA Expand Metabolomics Collaboration
News

BIOCRATES and ALTANA Expand Metabolomics Collaboration

BIOCRATES and ALTANA Expand Metabolomics Collaboration
News

BIOCRATES and ALTANA Expand Metabolomics Collaboration

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BIOCRATES and ALTANA Expand Metabolomics Collaboration"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Based on successful pilot studies in high-resolution pharmacodynamics, BIOCRATES Life Sciences GmbH and ALTANA Pharma AG signed a collaboration contract comprising joint method development for targeted metabolite profiling as well as further preclinical and clinical studies.

“We are very pleased to gain an innovative pharma partner like ALTANA Pharma in one of our main business areas”, said Armin Graber Ph.D., BIOCRATES’ CEO. “This collaboration will broaden our analytical panel and adapt it to the needs of the pharmaceutical industry.”

The medical focus of the joint projects will be on a better understanding of inflammatory processes in respiratory diseases in view of the development of novel multiparametric biomarkers for drug development and therapy monitoring.

“A targeted and quantitative approach to metabolomics allows to immediately deduce biologically relevant information from the analytical data”, says Klaus Weinberger Ph.D., CSO of BIOCRATES. “Important enzymatic reactions and entire metabolic pathways can now be monitored on a fully standardized basis.”

“Pilot studies in disease model characterization and pharmacodynamics have impressively demonstrated the huge potential of this technology for drug development”, adds Sascha Dammeier Ph.D., Head of Protein Technologies at ALTANA Pharma AG. “We aim at exploiting this potential to obtain additional relevant mode-of-action data in many steps of preclinical and clinical drug development.”

Advertisement